|

AZD6738 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 2

Top Sponsors

  • Seoul National University Hospital1
  • Institute of Cancer Research, United Kingdom1

Indications

  • Cancer2
  • HRD1
  • Bile Duct Cancer1
  • Triple Negative Breast Cancer (TNBC)1
  • Chemotherapy Effect1

Other2 trials

AZD6738 Plus Durvalumab in Biliary Tract Cancer
Phase 2
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.